Numerous molecular markers have been investigated as potential predictors of tumor responses to preoperative chemoradiotherapy (preCRT) for rectal cancer.
To develop a system in which biomarkers are used to predict the likelihood of a pathologic complete response (pCR) to preCRT.
This is a retrospective analysis of tumor specimens collected prior to preCRT from 81 patients who underwent curative resection for primary rectal adenocarcinoma between June 2008 and February 2012.
Using tissue microarrays and immunohistochemistry, expression levels of twelve candidate biomarkers (p53, p21, Bcl2, Bax, EGFR, Cox-2, MLH-1, MSH-2, Ku70, VEGF, TS, Ki-67) were evaluated in paraffin-embedded tumor samples collected before preCRT. The correlation between biomarker expression levels and the pathologic response to preCRT was assessed based on histopathological staging (pTNM) and tumor regression grade (TRG).
Expression levels of 4 biomarkers (p53, VEGF, p21, Ki67) correlated with pCR. Patients showing low expression of p53 and/or high expression of VEGF, p21, and Ki67 exhibited a significantly greater pCR rate. A scoring system devised so that one point was given for each biomarker whose expression level correlated with pCR (score range: 0–4) showed that 1 of 26 patients with scores of 0 to 1 achieved pCR, whereas 26 of 55 patients with scores of 2 to 4 achieved pCR (3.8% vs. 47.3%, p < 0.001). For prediction of pCR, the scoring system showed 96.3% sensitivity, 46.3% specificity, a 47.3% positive predictive value, and a 96.2% negative predictive value.
Immunohistochemistry has limitations related to reproducibility and the ability to provide quantitative information. In addition, this study lacks test and validation sets.
Expression levels of 4 biomarkers correlated with pCR after preCRT for rectal cancer. A scoring system based on levels of biomarker expression showed good sensitivity and negative predictive value for pCR.
1Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
2Department of Radiation Oncology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
3Department of Medical Oncology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
4Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Financial Disclosure: Nam Kyu Kim is currently receiving a 2011 faculty research grant (6-2011-0138) from Yonsei University College of Medicine. The authors claim no conflicts of interest.
Podium presentation at the 2013 American Society of Colon and Rectal Surgeons Meeting, Phoenix, Arizona, April 27 to May 1.
Correspondence: Nam Kyu Kim, M.D., Ph.D., Department of Surgery, Severance Hospital, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-Gu, Seoul 120–752, Korea. E-mail: firstname.lastname@example.org